Struggling Mereo Biopharma Group plc disclosed six-month data from the open-label arm of its phase IIb dose-ranging study in adults with type I, III or IV osteogenesis imperfecta treated with BPS-804 (setrusumab). Denise Scots-Knight, Mereo's CEO, said results from the Asteroid study were in line with company expectations and she expects 12-month headline data from blinded arms of the study in the second half of this year.